Valiant Laboratories Limited (VALIANTLAB) Fair Value & Analysis

Healthcare · IN · Market cap ₹3.5B

Below-average quality, and screening another 91% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹11.37). The favourable scenario is already priced in.
• Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The model range is unusually wide (₹4.37 to ₹11.37). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (3 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

34‑month range ₹50.93 – ₹204.80 · fair‑value band ₹4.37 – ₹11.37 · the ₹86.53 price screens above the ₹7.87 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Valiant Laboratories Limited (VALIANTLAB) currently trades at ₹86.53, while our model-based Fair Value estimate is ₹7.87, implying the stock looks roughly 90.9% overvalued today. The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Valiant Laboratories Limited generated revenue of ₹2.4B at a net margin of -1.4%. Revenue grew 59.2% year over year. It earns a return on equity of -1.2%. Net debt stands at ₹392M. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹4.37 (bear case) to ₹11.37 (bull case); at ₹86.53, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 75% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -91%, VALIANTLAB screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (₹38.35) versus Multiples (₹12.60). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever.

Full company description

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Valiant Laboratories Limited reported revenue of ₹2.4B in FY2026 versus ₹2.9B in FY2022, a compound −5.0%/yr. Reported net income was −₹32.7M in FY2026.

VALIANTLAB screens 91% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.